Flurry of Medicare Advantage and Part D Changes Includes Significant Policy Shifts

by McDermott Will & Emery
Contact

McDermott Will & Emery

In Depth

Last week, the Centers for Medicare & Medicaid Services (CMS) released not one but two documents with significant policy and operational implications for Medicare Advantage Organizations (MAOs) and Part D Sponsors: a final regulation (Final Rule) stemming from a proposed rule issued in November 2017 and the Calendar Year (CY) 2019 Announcement and Final Call Letter (Final Call Letter). These documents—along with the Bipartisan Budget Act of 2018 (BBA) that was passed in January—implement significant changes to the Medicare Advantage (MA) and Part D programs.

In particular, MAOs are gaining greater flexibility to design targeted benefits and offer new types of benefits to members. MAOs and Part D Sponsors will also enjoy somewhat diminished administrative burdens under the new rules. Other significant policy shifts affect the Quality Star Ratings program, the MA risk adjustment model, physician incentive plan (PIP) rules, and medical loss ratio (MLR) requirements.

With respect to the Part D program specifically, CMS has issued new clarifications of the federal any willing pharmacy (AWP) standard and finalized new requirements for Part D Sponsors to address opioid overutilization.

Expanded Flexibility for MAOs to Target Benefits Based on Health Status

In combination, the BBA, the Final Rule, and the Final Call Letter implement significant changes to the uniform benefit, supplemental benefit, and meaningful difference rules, giving MAOs substantially more flexibility in designing and targeting benefits for members with specialized medical needs.

These changes could have a transformative effect on the MA program by encouraging MAOs to offer a wider variety of plans that are targeted to different populations, but the actual impact may depend on actuarial and financial considerations that are integral to benefit design determinations. Specifically, MAOs will now have expanded flexibility in the following areas:

  • Uniform Benefits. Pursuant to federal law and regulation, MAOs are required to offer plans with uniform benefits, premiums, and cost-sharing throughout the plan’s service area. CMS has historically interpreted this mandate to mean that all basic benefits and supplemental benefits must be available equally, at the same level of cost-sharing, to all members throughout a particular service area. CMS stated in the preamble to the Final Rule that it is revising its interpretation of the uniform benefit requirement, though the regulatory standard set forth at 42 CFR § 422.100(d)(2) is unchanged.

Beginning in CY 2019, CMS will permit variation in cost-sharing and supplemental benefits based on health status or disease state. For example, an MAO will be permitted to offer diabetic members lower cost-sharing on endocrinologist visits and expanded access to foot care as a supplemental benefit. The medical criteria used for these targeted variations in benefits must meet certain standards established by CMS. In addition to this new interpretation of the uniform benefit requirement, Congress has given CMS authority, beginning in CY 2020, to waive the statutory uniform benefit requirement entirely for enrollees that are chronically ill, as defined under the BBA. 

  • Supplemental Benefits. The BBA and the Final Call Letter also create new flexibility for MAOs to offer a substantially expanded array of supplemental benefits. Under the Social Security Act, CMS only has the authority to permit MAOs to offer supplemental “health care benefits” and has historically enforced this requirement by mandating that supplemental benefits be “primarily health related.”

With the passage of the BBA, Congress has now authorized CMS to approve supplemental benefits for chronically ill enrollees that “have a reasonable expectation of improving or maintaining the health or overall function of the member” even if they are not primarily health related. In addition to this change for chronically ill enrollees, CMS has also expanded its interpretation of “primarily health related” for supplemental benefits available to all members.

OTSPicture

These changes are significant because they will open the door for substantially greater variation in benefits among MAOs and will permit experimentation with services that address underlying social determinants of health. MAOs will likely be able to cover non-skilled in-home care to assist with activities of daily living (e.g., dressing, eating, bathing), and may even be able to cover those services when they are provided by assisted living centers where members reside. The ability to offer these supplemental benefits may accelerate the trend of assisted living centers offering their own MA plans and/or foster new co-branding partnerships between MAOs and assisted living centers.

CMS has promised to issue clarifying guidance regarding the supplemental benefits authority in advance of CY 2019 bid submission. Depending on the scope of this guidance, other potential supplemental benefits that may be subject to expansion under these rules include home safety devices, expanded grocery and meal delivery services, and non-emergency transportation.

Expanding the scope of reimbursable health care services may seem inconsistent with an effort to decrease overall health care costs. But there is a growing recognition that social determinants of health impose real health care costs on the system. Bringing a broader array of services within the “health care” umbrella may enable MAOs to address these factors and ultimately control costs, or at least experiment with the hypothesis that these expanded benefits will improve health and reduce overall medical expenditures for MA enrollees.

  • Other Changes: Meaningful Difference, Value-Based Insurance Design, and Telehealth. As part of the Final Rule, CMS also repealed the MA meaningful difference rules (42 CFR §§ 422.254 and 422.256), which opens the door for MAOs to take full advantage of the expanded uniform benefit and supplemental benefit rules described above. Without the meaningful difference limitation, MAOs will now have the ability to offer multiple plans with slightly varied benefit designs in order to target new disease- and condition-specific benefit plans towards particular populations. The BBA also expanded the Value-Based Insurance Design model into a national demonstration project and provided new authority for MAOs to offer telehealth benefits beyond Original Medicare limitations as basic benefits beginning in CY 2020. Both of these changes will create additional flexibility and new opportunities within the MA program.

As previously noted, CMS has promised to issue additional guidance on revised uniform benefit and supplemental benefit rules in advance of CY 2019 bid submission. With June rapidly approaching, MAOs may not have time to implement substantial changes in their benefits for CY 2019, but greater variation may be seen in the coming years.

Changes to MA Risk Adjustment Model

CMS finalized a number of provisions related to payments to MAOs in the Final Call Letter. Significantly, CMS finalized changes to the CMS-Hierarchical Condition Category (HCC) risk adjustment model and will begin relying more heavily on encounter data in the calculation of risk scores.

  • CMS-HCC Risk Adjustment Model. CMS adjusts payments to MAOs based on the health status of their enrollees using the CMS-HCC risk adjustment model. CMS finalized some proposed changes to the model for 2019, including the addition of HCCs for chronic kidney disease, mental health conditions, and substance use disorders. Perhaps most significantly, CMS decided not to finalize its proposal to add a new coefficient to represent the number of conditions a beneficiary has. CMS stated that it plans to phase-in this proposal, which is mandated by the 21st Century Cures Act, beginning in 2020.
  • Encounter Data. CMS finalized its proposal to calculate 2019 risk scores by weighting the risk score calculated with encounter data and fee-for-service (FFS) diagnoses at 25 percent and the risk score calculated with Risk Adjustment Process System (RAPS) and FFS diagnoses at 75 percent. This is a change from the 2018 risk scores, which were calculated weighting the encounter data-based risk score at 15 percent. CMS’s transition to the use of encounter data has been slow and plagued by operational and technical issues, leading some, including the Government Accountability Office, to question the reliability of encounter data. In order to address some of the concerns, CMS finalized its proposal to supplement the encounter data with inpatient RAPS data, noting that “[e]ncounter [d]ata inpatient submissions are low compared to corresponding RAPS inpatient submissions” and that using the “inpatient diagnoses from RAPS will improve the completeness of the data.” CMS stated that it intends this supplementation with RAPS data to be temporary.

New Star Ratings Regulations Address Consolidations and Data Integrity Downgrades

For the first time, CMS has finalized regulations implementing the Quality Star Ratings program, under which MAOs and Part D Sponsors are assigned ratings used in plan marketing and for Quality Bonus Payments (QBPs), which has previously been almost entirely governed through subregulatory guidance. In addition to codifying existing standards, CMS finalized a number of changes to its Quality Star Ratings policies. Most notably, CMS changed the way in which it calculates the Star Ratings for contracts that have recently been consolidated and contracts with data integrity problems.

  • Consolidated Contracts. CMS will use an enrollment-weighted average to calculate the Star Ratings for recently consolidated contracts of the same plan type under the same parent organization. The enrollment-weighted average will be used for two years after consolidation. CMS initially proposed this change in its November proposed rule; Congress subsequently mandated the change in the BBA, on a quicker time frame than CMS had proposed. As a result, this new method will be effective for contract consolidations that are approved on or after January 1, 2019.
  • Data Integrity Downgrades. CMS codified its policy of reducing Star Ratings when a contract’s data is “inaccurate, incomplete, or biased” and finalized its proposal to scale certain reductions. Under CMS’s previous data integrity policy, CMS would downgrade a contract’s Star Rating on a particular measure to 1 star when the Agency deemed the contract’s data to be “inaccurate, incomplete, or biased,” a concept only vaguely discussed in subregulatory guidance. The final regulations set forth a somewhat more concrete policy that is generally specific to the type of measure at issue. For appeals measures, CMS will reduce ratings by 1, 2, 3, or 4 stars depending on the degree to which data is missing.

Updates to PIP Rules to Reflect Changing Market

CMS updated the PIP stop loss deductible limits for the first time since the Agency promulgated the current PIP regulation at 42 CFR § 422.208 in 2000. Under the PIP rules, a physician or physician group that has more than 25 percent of its potential payments tied to the cost of referral services (i.e., is at “substantial financial risk”) must obtain stop loss coverage. The PIP rules have taken on increased significance as MAOs have increasingly adopted value-based reimbursement models where physicians or physician groups are compensated based on managing the cost of referral services.

The Final Rule significantly increases the maximum deductible limits for the required stop loss coverage. Further, the maximum deductible amounts will be updated every 2 to 3 years to account for cost inflation and utilization changes. Also, as an alternative to stop loss coverage consistent with the patient panel-deductible standards, MAOs may provide stop loss coverage that is certified by an actuary as actuarially equivalent to the coverage under the patient panel-deductible standards.

In addition to the new deductible limits, CMS provided further guidance regarding the application of the PIP rules:

  • Arrangements with Intermediaries. CMS addressed the application of PIP rules to MAO arrangements with intermediaries, such as IPAs and MSOs, using five examples in the preamble; however, CMS did not codify these examples in the regulatory text. CMS provided specific guidance for situations in which the intermediary receives a bonus from the MAO based on the downstream physician’s or physician group’s ability to manage referral costs.
  • Payment for Stop Loss. CMS confirmed that MAOs may require providers to pay for stop loss coverage.
  • Patient Panel Size. Non-risk patients may be included in the patient panel size calculation by using the annual claims for non-risk patients divided by the estimated per member per year payment for a capitated patient.
  • Upside-Only Arrangements. CMS confirmed that the PIP rules do apply to upside-only arrangements.
  • Future Changes. CMS is considering more fundamental changes to the PIP rule framework and plans to engage stakeholders in future discussions.

MLR Clarifications and Relief on Reporting Burdens

In the Final Rule, CMS finalized several changes to the MA and Part D MLR requirements, including changes with respect to how expenses for fraud reduction activities and medication therapy management (MTM) count for the purposes of the MLR calculation.

  • Fraud Reduction Activities. Under the Final Rule, all fraud reduction expenses will qualify as quality improvement activity expenses, including fraud prevention, fraud detection, and fraud recovery. This is a more generous reporting standard than the current MLR rules under which MAOs are permitted to exclude from incurred claims the amount of claims payments recovered through fraud reduction efforts, up to the amount of fraud reduction expenses. This change only affects the MA and Part D program MLR requirements; the commercial and Medicaid MLR standards are not affected.
  • MTM. CMS clarified that all MTM programs that meet Part D requirements will qualify as quality improvement activity expenses.

In addition to the changes described above, CMS will significantly reduce the amount of information that MAOs must provide in their annual MLR reports. Rather than providing line item information about the various expense categories, MAOs will now be required to provide only their organization name, contract number, adjusted MLR, and the remittance amount (if any). Despite the streamlined reporting obligation, MAOs should consider keeping more detailed records internally both to improve the accuracy of the reported MLR and to use in the event of a CMS audit.

New Tools and Obligations for Part D Sponsors in Combatting Opioid Overutilization

Both the Final Rule and the Final Call Letter contain provisions aimed at addressing opioid overutilization. The final regulations and policies provide Part D Sponsors with new tools with which to fight overutilization and abuse, but they also impose new expectations on Part D Sponsors. The new policies include the following:

  • Part D Sponsors must implement a hard safety edit to limit opioid prescriptions for acute pain to no more than a seven day supply;
  • Part D Sponsors may implement a “lock-in” whereby they can limit at-risk members’ coverage for frequently abused drugs to certain providers and pharmacies;
  • Part D Sponsors may apply member-specific point-of-sale claim edits;
  • Part D Sponsors are expected to implement:
    • Real-time safety edits to engage members and prescribers about overdose risk and prevention;
    • An opioid care coordination edit at 90 morphine milligram equivalents per day; and
    • Additional “soft” safety edits to alert pharmacies about duplicative opioid therapy and concurrent use of opioids and benzodiazepines;
  • Part D Sponsors are expected to have a written strategy for addressing overutilization of opioids; and
  • Part D Sponsors may establish a drug management program for at-risk beneficiaries.

In addition to complying with the new requirements and expectations, CMS also reminds Part D Sponsors that they should not let the new programs and edits interfere with members’ access to medication-assisted treatment, such as buprenorphine.

Limited Clarifications of AWP Policy

While CMS implemented limited regulatory changes in connection with Part D pharmacy contracting, and ultimately declined to finalize a proposed definition of mail order pharmacy, the preamble to the Final Rule contains a long and expansive discussion of the Part D AWP requirements. This includes several “clarifications” of existing policy that may be seen by Part D Sponsors as going beyond existing guidance from CMS. For example, CMS expressed concerns about Part D Sponsors prohibiting retail pharmacies from delivering drugs by mail, but clarified that such pharmacies may need to enter into additional contracts with Part D Sponsors and that it would be reasonable to impose additional terms and conditions on such pharmacies specific to the mailing of prescription drugs. In addition, despite much discussion of accreditation requirements in the Proposed and Final Rules, CMS stated that it would not finalize any specific limitations on Part D plan accreditation requirements for pharmacies.

In perhaps the most significant regulatory change related to pharmacy contracting, CMS lengthened the time frame for Part D Sponsors to respond to pharmacy requests for standard contracting terms and conditions. Under current subregulatory guidance—which the Proposed Rule would have codified—the time frame for providing such standard terms and conditions is two business days from the date of the pharmacy’s request. The Final Rule lengthens this time frame to seven business days, effective January 1, 2019. CMS also clarified that “it is incumbent upon the pharmacy to request terms and conditions that are applicable to the business model(s) and types of services the pharmacy provides so that the terms and conditions offered are reasonable and relevant” to that particular pharmacy, laying to rest any ambiguity about which terms and conditions must be provided to requesting pharmacies.

*****

In addition to the topics discussed above, the Final Call Letter and Final Rule also address a variety of other regulatory areas, including:

  • Expanded access to electronic health data for MA enrollees;
  • Inclusion of health risk assessments in rewards and incentives programs;
  • Encounter data listening forums, monitoring, and compliance activities;
  • Electronic delivery for certain required member documents;
  • More limited CMS review of marketing materials;
  • An expanded open enrollment period for MA plans;
  • Generic substitutions of brand name drugs;
  • Treatment of biosimilars as generics for certain cost sharing requirements; and
  • Use of CMS’s new preclusion list for providers and prescribers.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© McDermott Will & Emery | Attorney Advertising

Written by:

McDermott Will & Emery
Contact
more
less

McDermott Will & Emery on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.